Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

8.880 -0.390 (-4.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2
Discover three top dividend stocks for stable income in April that combine sustainable returns and long-term growth. 
Via InvestorPlace
Looking Into Viatris's Recent Short Interest
Via Benzinga
Is Viatris a Great Dividend Stock or Just a Value Trap?
Investors can collect a high yield with Viatris, but is it a risky payout to rely on? 
Via The Motley Fool
2 Dirt Cheap Dividend Stocks to Buy and Hold
These companies aren't popular on the market right now, but income investors will like them. 
Via The Motley Fool
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
From Scott+Scott Attorneys at Law and Hedin Hall LLP
Via Business Wire
(VTRS) - Analyzing Viatris's Short Interest
Via Benzinga
Recap: Viatris Q3 Earnings
Via Benzinga
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last quarter of the year. 
Via Benzinga
Topics Economy
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments
Viatris and Idorsia collaborate on groundbreaking heart attack treatments, leveraging innovative therapies for acute conditions. 
Via Benzinga
3 Overextended Stocks That Need to Slash Their Dividends ASAP
The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big. 
Via InvestorPlace
3 Bargain Stocks to Snatch Up Before They Bounce Back
The market is a weighing machine in the long run, meaning these bargain stocks will deliver impressive forward returns. 
Via InvestorPlace
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
The Terrible Ten
Most of the aforementioned group of quotable experts expect some mean reversion for the top stocks in the S&P 500 and counsel avoiding market cap weighting in favor of equal weighting. 
Via Talk Markets
Topics Stocks
The Terrible Ten
Many strategists recommend equal weighting over cap-weighting, claiming that over time, equal weighting always outperforms. 
Via Talk Markets
These 9 Stocks Are Running To Start 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start. 
Via Investor's Business Daily
Topics Stocks
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS) 
Via Benzinga
Topics Lawsuit
Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Topics Economy
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist... 
Via Benzinga
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
Wednesday, a court ruling that found Viatris Inc's (NASDAQ: 
Via Benzinga
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value. 
Via Talk Markets
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace
7 Low P/E Stocks Poised to Rebound
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. 
Via InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback